| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/25/2003 | WO2003077855A2 N3 alkylated benzimidazole derivatives as mek inhibitors |
| 09/25/2003 | WO2003077840A2 Method of modulating inflammatory response |
| 09/25/2003 | WO2003077836A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 09/25/2003 | WO2003077834A2 Central airway administration for systemic delivery of therapeutics |
| 09/25/2003 | WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes |
| 09/25/2003 | WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque |
| 09/25/2003 | WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 09/25/2003 | WO2003042246A3 Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| 09/25/2003 | WO2003040313A3 Il-21 antagonists |
| 09/25/2003 | WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
| 09/25/2003 | WO2003013537A3 Irinotecan for treatment of cancer |
| 09/25/2003 | WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 09/25/2003 | WO2003011910A3 Anti-ssrp-1 monoclonal antibodies and hybridomas producing said antibodies |
| 09/25/2003 | WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof |
| 09/25/2003 | WO2003011331A3 Materials and methods relating to improved vaccination strategies |
| 09/25/2003 | WO2003007924A3 Combinations comprising epothilones and pharmaceutical uses thereof |
| 09/25/2003 | WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 09/25/2003 | WO2003000907A3 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation |
| 09/25/2003 | WO2003000709A3 Sialic acid derivatives for use as siglec inhibitors |
| 09/25/2003 | WO2002100412A3 Stabilized dispersion of phytosterol in oil |
| 09/25/2003 | WO2002097059A9 Chromosome-based platforms |
| 09/25/2003 | WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 09/25/2003 | WO2002092826A3 Composition and method for treating cancer using herpes virus |
| 09/25/2003 | WO2002092635A3 Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| 09/25/2003 | WO2002081705A3 Regulation of human gnat acetyltransferase-like protein |
| 09/25/2003 | WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 09/25/2003 | WO2002069995A3 Use of trail and antiprogestins for treating cancer |
| 09/25/2003 | WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89) |
| 09/25/2003 | WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 09/25/2003 | WO2002063004A3 G-protein coupled receptors |
| 09/25/2003 | WO2002062368A3 Method of inducing a ctl response |
| 09/25/2003 | WO2002061128A3 Method of determining a chemotherapeutic regimen based on ercc1 expression |
| 09/25/2003 | WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 09/25/2003 | WO2002036161A3 Novel targeted compositions for diagnostic and therapeutic use |
| 09/25/2003 | WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 09/25/2003 | WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 09/25/2003 | WO2002028432A3 Stem cell-based methods for preventing and treating tumor |
| 09/25/2003 | WO2002026982A3 Secreted human proteins |
| 09/25/2003 | WO2002020846A3 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 09/25/2003 | WO2002014489A9 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 09/25/2003 | WO2002014368A3 Proteins and nucleic acids encoding the same |
| 09/25/2003 | WO2002013833A3 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
| 09/25/2003 | WO2002010378A3 Antisense modulation of ptp1b expression |
| 09/25/2003 | US20030182668 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
| 09/25/2003 | US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/25/2003 | US20030181716 Novel azepane derivatives |
| 09/25/2003 | US20030181689 Percarboxylated polysaccharides, and a process for their preparation |
| 09/25/2003 | US20030181687 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 09/25/2003 | US20030181662 Human procalcitonin and the preparation and use thereof |
| 09/25/2003 | US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers |
| 09/25/2003 | US20030181587 Thermoplastic resin composition |
| 09/25/2003 | US20030181530 Soluble compositions of triphenylethylene antiestrogens |
| 09/25/2003 | US20030181529 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 09/25/2003 | US20030181519 Substituted phenyl naphthalenes as estrogenic agents |
| 09/25/2003 | US20030181514 Therapeutic compounds and methods |
| 09/25/2003 | US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 09/25/2003 | US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 09/25/2003 | US20030181487 Salts of benzimidazole compound and use thereof |
| 09/25/2003 | US20030181481 Therapeutic drugs for treating central nervous system disorders |
| 09/25/2003 | US20030181480 Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds |
| 09/25/2003 | US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 09/25/2003 | US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof |
| 09/25/2003 | US20030181474 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/25/2003 | US20030181473 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/25/2003 | US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 09/25/2003 | US20030181467 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| 09/25/2003 | US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants |
| 09/25/2003 | US20030181454 Nitrogen compounds and prodrugs used as type-II secretory phospholipase(sPLA2) agonists or antagonists, for prevention cancer, cirrhosis, Alzheimer's disease and/or arteriosclerosis |
| 09/25/2003 | US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate |
| 09/25/2003 | US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents |
| 09/25/2003 | US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 09/25/2003 | US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents |
| 09/25/2003 | US20030181439 Use of paullone derivatives for making medicines |
| 09/25/2003 | US20030181429 Topically applying betulinic acid or a betulinic acid derivative to tumor site |
| 09/25/2003 | US20030181427 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| 09/25/2003 | US20030181424 Compositions with vascular damaging activity |
| 09/25/2003 | US20030181420 Modulators of LXR |
| 09/25/2003 | US20030181394 Carbobydrates such as alpha-D-galactopyranosyl-1,2-glycerol and/or isomers, obtained by solvent extraction from algae, for use as viricides or anticarcinogenic agents |
| 09/25/2003 | US20030181385 The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N- acyl moiety, a dipolar moiety, a sulfonium |
| 09/25/2003 | US20030181362 Receptor |
| 09/25/2003 | US20030181360 Human TSLP DNA and polypeptides |
| 09/25/2003 | US20030181359 Tripeptide prodrug compounds |
| 09/25/2003 | US20030180947 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression |
| 09/25/2003 | US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 09/25/2003 | US20030180931 Cellubrevin homologs |
| 09/25/2003 | US20030180877 Gene therapy; drug screening |
| 09/25/2003 | US20030180818 Isolated nucleic acid molecules encoding human peptidoglycan recognition protein-related proteins, referred to PGRP-K (keratinocytes), PGRP-W (wound healing) and PGRP-C (chondrosarcoma) |
| 09/25/2003 | US20030180817 Determining levels of a colon specific gene in the cells, or bodily fluids in a patient, comparing determined levels of CSG with levels of CSG in cells from normal human control, wherein a change in level of CSG indicates presence of cancer |
| 09/25/2003 | US20030180810 For diagnosis, prevention, and treatment of reproductive disorders, Alzheimer's disease, cancer, immunological disorders, and diabetes |
| 09/25/2003 | US20030180805 Methods and compositions for derepression of IAP-inhibited caspase |
| 09/25/2003 | US20030180799 Antibodies against plasma cells |
| 09/25/2003 | US20030180786 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/25/2003 | US20030180778 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3 |
| 09/25/2003 | US20030180744 High affinity oligonucleotide ligands to growth factors |
| 09/25/2003 | US20030180739 Culturing a cell in the presence or absence of the compound, assaying the cell for expression or activity of gene(s), detecting the compound when expression of the genes is lower in the presence of the compound than in the absence |
| 09/25/2003 | US20030180707 Recombinant expression construct encoding a reporter gene operably linked to a promoter from a gene the expression of which is induced by a retinoid, wherein the promoter does not contain a retinoic acid response elements site |
| 09/25/2003 | US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
| 09/25/2003 | US20030180394 Extracts from sophora species, method for producing the same and their use |
| 09/25/2003 | US20030180383 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 09/25/2003 | US20030180382 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |